Glenmark Chief on Cracking the Multi-Specific Code
Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company’s 25-year innovation bet, and why it’s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark’s IGI platform after fifteen years of R&D. Saldanha talks through the platform’s pipeline, why Glenmark stays out of ADCs and CAR-T, how it’s building “Glenmark 3.0” across oncology, dermatology and respiratory, and why he still rates the US well ahead of China on innovation. The…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.